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AbstrAct
Introduction The numbers of patients with three or more 
chronic conditions (multimorbidity) are increasing, and 
will rise to 2.9 million by 2018 in the UK alone. Currently 
in the UK, conditions are mainly managed using over 
250 sets of single-condition guidance, which has the 
potential to generate conflicting recommendations for 
lifestyle and concurrent medication for individual patients 
with more than one condition. To address some of these 
issues, we are developing a new computer-based tool 
to help manage these patients more effectively. For this 
tool to be applicable and relevant to current practice, we 
must first better understand how existing patients with 
multimorbidity are being managed, particularly relating to 
concerns over prescribing and potential polypharmacy.
Methods and analysis Up to four secondary care 
centres, two community pharmacies and between four 
and eight primary care centres in the West Midlands will 
be recruited. Interviewees will be purposively sampled 
from these sites, up to a maximum of 30. In this mixed 
methods study, we will perform a dual framework 
analysis on the qualitative data; the first analysis will use 
the Theoretical Domains Framework to assess barriers 
and enablers for healthcare professionals around the 
management of multimorbid patients; the second analysis 
will use Normalisation Process Theory to understand how 
interventions are currently being successfully implemented 
in both settings. We will also extract quantitative 
anonymised patient data from primary care to determine 
the extent of polypharmacy currently present for patients 
with multimorbidity in the West Midlands.
Discussion We aim to combine these data so that we can 
build a useful, fully implementable tool which addresses 
the barriers most amenable to change within both primary 
and secondary care contexts.
Ethics and dissemination Favourable ethical approval 
has been granted by The University of Birmingham 
Research Ethics Committee (ERN_16–0074) on 17 May 
2016. Our work will be disseminated through peer-
reviewed literature, trade journals and conferences. We will 
also use the dedicated web page hosted by the University 
to serve as a central point of contact and as a repository 
of our findings. We aim to produce a minimum of three 
articles from this work to contribute to the international 
scientific literature.
Protocol registration number NIHR Clinical Research 
Network Portfolio Registration CPMS ID 30613.
IntroDuctIon
In the UK there is a focus on the forma-
tion and implementation of guidelines to 
help standardise and improve the quality 
of care.1–3 Providers may choose to trans-
late this guidance into local policy to help 
implementation, for example, a multidis-
ciplinary care plan which details essential 
steps in the management of patients with 
a specific clinical problem.4 These path-
ways frequently use graphical descriptions 
of evidence and options and are typically 
represented in single, or series of, flow 
charts5 6 and have been shown to have the 
possibility to improve care if they are imple-
mented correctly.7 These systems will contain 
prompts or reminders which in isolation can 
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Protocol
strengths and limitations of this study
 ► We are using a series of semi-structured interviews 
to elicit current barriers found within both primary 
and secondary care when managing patients with 
multimorbidity.
 ► This will be complemented by the first quantitative 
exploration of polypharmacy in multimorbid patients 
in primary care by interrogating routinely collected 
prescribing data within the same practices.
 ► This pilot study is based in the West Midlands whose 
diverse population means that a range of practices 
and clinicians will be participating.
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help to improve practice8–10 but in combination can lead 
to alert fatigue.11
Of the 250 clinical guidelines published by the National 
Institute for Health and Care Excellence,12 only four 
account for more than one condition. This presents 
issues for clinicians attempting to use this guidance to 
manage multimorbidity. Defined as two or more chronic 
conditions in the same individual,13patients with multi-
morbidity are becoming more prevalent and it is esti-
mated that by 2018 the number of people in the UK with 
three or more long-term conditions will have grown to 
2.9 million.14 Using multiple single condition guide-
lines means patients can be left with a significant treat-
ment burden15 16 and conflicting advice around lifestyle 
factors.17 There are also implications for clinicians who 
struggle to balance the requirements of several guide-
lines for multimorbid patients, hindered by the lack of 
outcome data.18
One significant consequence of following multiple guide-
lines is the concurrent prescribing of multiple medications. 
This phenomenon has been termed ‘polypharmacy’19 and 
has been identified as a complicating issue for patients with 
multimorbidity.20 The chances of polypharmacy greatly 
increase when several sets of guidance are being imple-
mented in patients with multimorbidity21 and healthcare 
professionals recognise that fulfilling multiple guidelines 
might compromise patient-centred care.22 There is evidence 
this simultaneous medication administration can lead to an 
increased risk of patient hospitalisation23 24 and work has 
begun to reduce this risk,25 focusing on reducing inappro-
priate prescribing of non-steroidal anti-inflammatory drugs, 
proton pump inhibitors and duplicate therapy.26 However 
progress is inconsistent and large interpractice variation in 
levels of polypharmacy remains.27
In response to the issues raised in managing increasing 
numbers of multimorbid patients there have been calls 
in the UK for improved integration of existing guide-
lines28 with the maxim ‘treat the patient, not the disease’. 
In response the 'MITCON' (Automated Conflict Reso-
lution in Clinical Pathways)  project has begun which 
involves the development of a new computer based tool 
which will automatically detect conflict between guide-
lines (Litchfield I, Turner A, Backman R et al. Automated 
conflict resolution between multiple clinical pathways. 
2017. Unpublished). To ensure that this tool is appli-
cable and relevant we need to understand how multiple 
guidelines are being translated into existing systems and 
processes and the extent and implications for patients 
and care providers of prescribing multiple medications. 
This protocol details the Mixed Methods Multimorbidity 
Study (MiMMS) which seeks to both identify barriers 
and facilitators to successful guideline implementation, 
and determine current levels of polypharmacy in multi-
morbid patients in the West Midlands.
research questions
There are two distinct yet related research questions 
that we will answer. The first concerns the way in which 
guidelines are used in managing multimorbid patients in 
two settings—primary and secondary care. The second 
will involve a quantitative assessment of polypharmacy in 
multimorbid patients in primary care. Although previous 
work has explored multimorbidity, ours is the first to look 
at both primary and secondary care settings and corrob-
orate qualitative work with quantitative data on polyphar-
macy at the same general practitioner (GP) practices.
Managing multimorbidity
We will use the Theoretical Domains Framework 
(TDF)29 30 to identify barriers around managing patients 
with multimorbidity. This framework has been extensively 
validated within this setting,31–36 and allows linkage of 
behaviour change techniques30 37 if required later in the 
project. We will also use Normalisation Process Theory 
(NPT)38 to identify the current successful implementa-
tion strategies for guidelines and associated computer 
based tools used within current practice. This theory 
has also been extensively validated and can assess the 
process whereby new items become routine practice. To 
the best of our knowledge, this work is the first to use a 
dual framework approach for analysis. Furthermore, this 
work will seek to identify barriers in multiple National 
Health Service (NHS) settings so that the full patient 
pathway with a number of healthcare professionals can 
be explored.
Prevalence of multimorbidity
We aim to assess current levels of polypharmacy for up to 
six chronic conditions within primary care retrospectively 
over a 24-month period. In doing so, we will determine 
the percentage of patients that experience polypharmacy 
and whether there are patients with certain combinations 
of conditions that are most at risk. The literature indicates 
that our target conditions will occur in at least a pairwise 
combination. We will therefore perform pairwise compar-
isons of conditions to assess numbers of patients who have 
interactions within their prescribed medications.39–53 This 
will allow us to determine which combinations of condi-
tions are most frequently associated with polypharmacy. 
For this work we are defining multimorbidity as having 
two or more of our target conditions diagnosed with 
an active Read Code. We are defining polypharmacy as 
taking a minimum of two drugs at any one time point so 
that we can assess the interaction.
MEthoDs AnD AnAlysIs
settings and participants
Site recruitment
We will assess all primary care centres in the West Midlands 
for study eligibility (defined as using  Egton Medical 
Information Systems (EMIS) as their clinical system). We 
will also purposively sample up to four secondary care 
centres with differing patient demographics in the West 
Midlands. Finally, we will purposively sample up to two 
pharmacy centres.
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Figure 1 Flow diagram of the Mixed Methods Multimorbidity Study (MiMMS). Summary of participation from each of the 
National Health Service sectors with an analysis overview from the quantitative and qualitative methodology. GP, general 
practitioner.
Research design
We are using a mixed methods approach in this work and 
will be conducting the study in two interrelated phases 
(figure 1). Phase I is the qualitative exploration of the 
implementation of current guidelines including the 
barriers and enablers to the management of multimorbid 
patients in primary and secondary care settings including 
the use of clinical software systems. Phase II will use 
quantitative methods to explore the correlation between 
clinical condition combinations and the numbers of 
interacting medications prescribed in primary care.
Phase I
Site recruitment
In accordance with the theory of maximum variation,54 
between four and eight primary care sites and up to four 
secondary care sites will be recruited for this pilot from 
the West Midlands region. This will also help mitigate 
the risk of responder bias.55 Sites will be initiated once all 
research and development (R&D) approvals have been 
met, and all necessary documents have been returned to 
the coordinating centre.
Recruitment for these sites will occur through written 
expressions of interest via the Primary Care Research 
Network as well as opportunistic recruitment of GPs 
during appropriate educational meetings. We will 
use purposive sampling for the secondary care and 
community pharmacy sites and will aim to recruit 
within different working environments, for example, 
community pharmacy and pharmacists working within 
a GP practice, where possible. We will also interview 
healthcare professionals within different departments 
in secondary care.
Primary care sites that have EMIS web as their clinical 
system can participate in both phases of the project. We 
will aim to recruit healthcare professionals who have 
used other clinical systems such as The Phoenix Part-
nership (TPP) (SystmOne) or Vision to identify specific 
barriers relating to these systems.
Healthcare professionals’ recruitment
All healthcare professionals with experience either of 
managing patients with multimorbidity, or who have 
implemented new guidelines locally, will be invited to 
participate in phase I. In primary care we expect to 
recruit fully qualified and registrar-level GPs, advanced 
nurse practitioners and practice managers. Within 
secondary care we will recruit participants from special-
ties relevant to the six diseases targeted in the quanti-
tative work as well as elderly care physicians if possible. 
These will include, but not be limited to, consultants, 
senior registrars (at least ST4 and above) and advanced 
nurse practitioners. Additionally, we will aim to recruit a 
minimum of two community pharmacists. All sampling 
will be performed using an iterative snowballing 
approach.56
In each case we will aim to recruit at least two individ-
uals from each of the staff groups stated above, and we 
will continue with purposive sampling until data satura-
tion has been achieved.57
group.bmj.com on September 20, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
4 Backman R, et al. BMJ Open 2017;7:e016713. doi:10.1136/bmjopen-2017-016713
Open Access 
Data management
In-depth semi-structured interviews will be conducted 
using a topic guide tailored to both the NPT and TDF 
(supplementary file 1) so that both barriers around 
management of multimorbid patients and current 
guideline usage can be elicited. Prompts and examples 
will be used to ensure that data are captured and we will 
perform constant comparison analysis58 during the inter-
view process. In-depth semi-structured interviews will 
allow these specific topics to be covered, while retaining 
an element of narrative so that healthcare professionals 
can share the factors that are important to them. Inter-
viewees will always be given the opportunity to add 
anything they wish at the start and end of the interview. 
Field notes will be taken by the researcher, both to allow 
for continued professional development and also to 
take note of surroundings and reflection of important 
findings.
Where possible, participants will be sent a copy of the 
consent form and information sheet at least 24 hours 
before the interview so that they have time to consider 
taking part and also time to reflect on the challenges of 
managing these types of patients. Using a snowballing 
technique,56 sometimes known as the chain referral tech-
nique where an interviewee is asked to suggest a member 
of their team who may have further insights on a partic-
ular topic, this may not always be possible, so if partici-
pants require less time to decide to take part they may 
do so.
Fully informed consent will be taken by a trained 
researcher who holds a current good clinical practice 
certificate and all associated approvals. We recognise that 
healthcare professionals may feel uncomfortable sharing 
cases where they feel that patients may not have been 
managed to the published guidance, however all partic-
ipants will be reassured that not all questions have to be 
answered and the interview can stop at any time. Any data 
that could identify the individual practice, or patient, will 
be anonymised prior to any form of dissemination. Partic-
ipants will have up to two weeks after the interview to with-
draw their data prior to data analysis.
We will aim to conduct 30 interviews, however, interviews 
will be stopped when data saturation has been reached 
and no new major themes are arising within the last five 
transcripts.59 60 Due to our interview topics being around 
a specific aspect of care, combined with interviewees 
having a similar role and training background we should 
achieve saturation within our recruitment target.61 We 
will aim to include at least two interviews from each group 
of healthcare professionals (consultants; specialist regis-
trars; GPs; GP registrars; practice managers; advanced 
nurse practitioners; community pharmacists). Purposive 
sampling will be used with snowballing to ensure that the 
correct mix of healthcare professionals is included.
Data analysis
All interviews will be recorded using a digital voice 
recorder and consent for this will be obtained prior to 
starting. Digital recordings will then be transcribed 
verbatim prior to analysis.
The returned document will be checked, both for 
queries and to ensure that anonymity is protected prior to 
being imported into a suitable analysis programme such 
as NVivo (V.11).
TDF will be the main conceptual framework used in 
the qualitative work. This has been validated in a series 
of primary and secondary studies29 31–36 62 63 as a method 
of understanding behaviour within a clinical setting. NPT 
will also be used and this framework has been developed 
to support the implementation and evaluation of complex 
interventions38 64 65 and has been used extensively in trials, 
systematic reviews and qualitative work.66 This theory will 
allow us to assess the ‘key ingredients’ when a guideline 
or local initiative has been successfully implemented in 
practice. This information will help us to include ingre-
dients for successful implementation of our new tool to 
help manage patients with multimorbidity more effec-
tively. Outside of these two frameworks, we will remain 
sensitive to new themes and will analyse iteratively.
Study outcomes
The outcomes for the qualitative work are:
 ► To assess how guidelines and other local initiatives are 
being implemented in the management of patients 
with multimorbidity within primary and secondary 
care with the outcome of defining ‘key ingredients’ 
for successful implementation; and
 ► To understand the barriers and enablers around 
managing multimorbidityincluding which factors are 
taken into consideration in making clinical decisions.
Phase II
Site recruitment
Primary care centres who have agreed to take part in 
phase I and have EMIS as their clinical system will be 
approached for phase II.
Participant recruitment/data collection
We will use custom-built code provided by PRIMIS (The 
University of Nottingham, Nottingham, UK, https://
www. nottingham. ac. uk/ primis/ index. aspx) which gener-
ates a report within the GPs’ clinical system. The code will 
be fully tested prior to use to ensure patient anonymity is 
protected. All eligible patients over the age of 18 years who 
have been registered at the practice for a minimum of 
three months will have data extracted relating to prescrip-
tions. For patients to be fully eligible they must also have 
a Read Code within their notes at any time for at least 
one of the target conditions (supplementary file 1) and 
have had at least one prescription issued within the last 
two years. All data will remain anonymous and we will 
extract one possible identifier, sex, to allow us to assess 
the population demographic. To ensure anonymity, age 
at the date of extraction will also be collected rather 
than date of birth. The code will produce three reports; 
one will detail the practice profile, one will detail the 
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Table 1 Estimates within UK primary care between 2014 and 2015
List size 
(total 
number)
List size (estimated 
30–74-year-
old patients)
CHD
(number on 
register)
Hypertension 
(number on 
register)
COPD
(number on 
register)
Diabetes mellitus, 
17 years and above
(number on register)
Depression 
(number on 
register)
Mean 7304 4049 237 1007 133 375 425
SD 4429 2446 167 650 98 233 338
IQR 5870 3323 215 854 119 301 400
CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; SD standard deviation; IQR inter-quartile range.
Table 2 Minimum and maximum estimates for selected conditions
4 GP practices 6 GP practices 8 GP practices
Estimated average list size 29 216 43 824 58 432
Estimated average list of 30–74-year-old patients 16 196 24 294 32 392
Estimated number of patients with CHD 948 1422 1896
Estimated number of patients with hypertension 4028 6042 8056
Estimated number of patients with COPD 532 798 1064
Estimated number of patients with diabetes mellitus 1500 2250 3000
Estimated number of patients with depression 1700 2550 3400
CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease.
conditions the patient has coded with the Read Code 
included and the final report will detail the drug history 
over the preceding 24 months.
Sample size
This study uses a retrospective audit approach to collect 
data, therefore there is limited scope for increasing 
the sample size as there is not a traditional recruitment 
component. Using the Quality Outcomes Framework 
(QOF) data from 2014 to 2015, the average prevalence 
and list size has been calculated in table 1. Currently, 
there is no register of patients with osteoarthritis, so these 
numbers are not available. Table 2 shows the estimated 
numbers extrapolated from table 1, modelling the effects 
of practice number. It is likely that these are minimum 
estimates as patients may have associated Read Codes but 
have not been included on the disease register. Currently 
we have no data for the number of prescribed drugs that 
currently interact for this population. Assuming that 10% 
of drugs prescribed have an interaction, we can assume 
that a minimum of 53 and a maximum of 806 parameters 
can be assessed (table 2) which will be sufficient for the 
fixed-effects model. Therefore in this pilot study we aim 
to recruit a minimum of four primary care centres up to 
a maximum of eight with the overall intention of using 
these data to form the basis of a sample size calculation 
in a larger study.
Data management
The QOF business rules V.34 will be used to extract Read 
Codes for five of our six target conditions (chronic obstruc-
tive pulmonary disease, type 2 diabetes, depression, 
coronary heart disease and hypertension). The general 
parent code will be used to extract patients suffering from 
osteoarthritis as there are currently no QOF indicators 
that are suitable for this (supplementary file 1). Every 
patient identified using these codes will have retrospec-
tive prescription data collected for the preceding 2 years. 
Unique subject identification numbers will be generated 
so that a comprehensive picture of prescriptions can be 
built up for each patient, while remaining anonymised. 
The clinical extraction code containing these details will 
be generated by a company with expertise in this area of 
work so that only relevant data are extracted and patient 
anonymity is preserved. We will not use a condition 
clustering approach and will only use the combinations 
of conditions as a way to characterise our population 
rather than drawing conclusions about prevalence of 
comorbidities.
After the patient’s drug history has been constructed 
using a process mining approach, we will use our new 
drug interaction tool to assess the numbers and types 
of conflicts. This tool is based on the British National 
Formulary (BNF) interactions list, so we will use the 
same categories of no interaction, mild interaction and 
severe interaction. We will also use the expertise of ML 
to enable the use of natural language processing within 
this data set to pull out the types of interaction. In addi-
tion we will use any relating to drug clearance to rein-
terpret those patients with chronic kidney disease (CKD). 
This work will help inform the software based tool that 
is being developed within the grant. We will also extract 
data relating to CKD stage and we will use these data to 
interpret our findings due to changes in renal function 
often triggering a change in prescriptions. We recognise 
that there are challenges managing patients with multi-
morbidity, and that there may be a time when drugs that 
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interact have to be used due to the clinical severity of one 
or more conditions. Therefore these data are not going 
to be linked to specific prescribers, and data will be fed 
back to practices in a pseudo-anonymised form.
A practice age demographic profile will be gained from 
the practice and publicly available QOF records, so that 
the results can be interpreted in the correct context. 
These results will also be compared with national records 
of disease profiling using the QOF disease registers and 
associated prevalence.
Data analysis
Data will be analysed using a fixed-effects model with 
interaction terms. The interaction term will be whether 
a drug pair is appropriate or inappropriate as defined 
using the BNF, the current gold standard method,67 with 
a variable of presence or absence of condition. Pairwise 
combinations of all conditions will be explored, as the 
literature suggests that each combination of two diseases 
has an evidence base. Our tool will complement existing 
prescribing support tools68 69 as it places prescribing 
support within the context of navigating multiple care 
pathways.
Study outcomes
The primary outcome for phase II is:
 ► To elicit the proportion of patients with pairwise 
condition combinations who have been prescribed 
two or more drugs concurrently, and the type of inter-
action, if any, between the two.
Further secondary outcomes for this work are to elicit:
 ► The total number, and severity, of interactions for 
each clinical condition as defined by the latest gold 
standard references.
 ► To compare the numbers of patients identified with 
these clinical conditions with the practice disease 
register and to the national reported prevalence using 
the latest available QOF data.
DIscussIon
This study protocol is using a mixed methods approach 
to better understand the challenges associated with 
multimorbidity and polypharmacy. In determining the 
utilisation of guidelines in the management of multiple 
morbidities we will use two methodological approaches. 
Both TDF29 31–36 62 63 and NPT have been rigorously 
evaluated and used within the NHS context.38 64–66 The 
dual analysis will enable a more robust understanding 
of the current issues. By extracting prescribing data on 
multimorbid patients for the first time we will be able to 
quantify the prevalence of polypharmacy in patients with 
combinations of some of the most common conditions. 
We will use this work to improve the implementability 
and acceptability of the new computer tool that is being 
formed as part of the MITCON grant. The MITCON 
tool will automatically detect conflict between guidelines 
to give healthcare professionals the most accurate and 
up-to-date information at the point of patient contact.
There are also a number of potential limitations with 
our approach. First, there is a risk of responder bias at 
both the practice recruitment and interviewee recruit-
ment stages. Our findings will not necessarily be repre-
sentative of the whole of the UK, however by conducting 
our study in the West Midlands we have the opportunity 
to recruit from a range of practices in terms of size and 
socioeconomic environment, and staff with a range of 
seniority and experience. Also, by conducting semi-struc-
tured interviews with individual members of staff we 
expect to reduce the impact of social desirability bias. 
Furthermore, the majority of our interviews in primary 
care are running the clinical system EMIS which may 
have different challenges to the other clinical systems 
currently running. We seek to address this by recruiting 
at a specialist educational meeting to include at least two 
GPs running a different clinical system. Also, during the 
training period, it is likely that GPs will have used other 
systems, so we will prompt around this area so that this 
limitation is minimised. Also, as this is a pilot study and 
we are not yet able to accurately estimate numbers of 
interactions we will focus on pairwise comparison initially. 
However, if it becomes apparent that many patients are 
taking three or four drugs, at the same time, that interact, 
we will analyse these separately. Furthermore, we are only 
able to assess six of the common morbidities in the UK, 
so there is a potential for missing excess morbidity as well 
as introducing bias relating to our chosen conditions. 
However, we have chosen prevalent chronic conditions 
which are all known to interact with each other, both 
within and between body systems. Finally, we are aware of 
larger studies assessing polypharmacy70 71 but to the best 
of our knowledge we are the first study to undertake a 
mixed methods approach within each primary care site.
The findings of each phase will be important in their 
own right but taken together they will provide a rigorous 
and robust description of the current issues around 
managing multimorbidity and the prevalence of poly-
pharmacy. This information will prove invaluable in the 
development of our novel software tool to ensure that it 
can be tailored to barriers most amenable to change.
trIAl stAtus
At the time of submission, this study was actively recruiting 
centres and participants and no analysis work has yet been 
undertaken.
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